Institute director Dr Jinda Rojanamethin said the study would examine the immune response to the SARS-CoV-2 virus after Covid-19 vaccination in cancer patients.
The target group for the trial is cancer patients who are at least 18 years old and are currently undergoing treatment or have been treated in the last six months. The vaccine being used in the trial is the Sinovac brand.
Volunteers will be injected with two doses of Sinovac vaccine, four weeks apart.
Their immune response will be measured via blood tests before, and two weeks after the second dose. This will help gauge how much protection against the virus Covid-19 vaccine offers cancer patients.
Published : May 19, 2021
By : The Nation